Format

Send to

Choose Destination
Haematologica. 2019 Sep 19. pii: haematol.2019.219790. doi: 10.3324/haematol.2019.219790. [Epub ahead of print]

Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: consensus recommendations from the acute leukemia working party of the EBMT.

Author information

1
Department of Hematology-Oncology, Vanderbilt University Medical Center, Nashville, TN, USA; bhagirathbhai.r.dholaria@vumc.org.
2
Department of Hematology-Oncology, Vanderbilt University Medical Center, Nashville, TN, USA.
3
Department of Haematology, Saint Antoine Hospital, Paris, France.
4
Johns Hopkins University School of Medicine, Baltimore, MD, USA.
5
Department of Pediatric Hematology/Oncology, Ospedale Pediatrico Bambino Gesù, Rome, Italy.
6
Department of Laboratory Medicine, Karolinska Institutet and University Hospital, Stockholm, Sweden.
7
City of Hope National Medical Center, Duarte, CA, USA.
8
Stem Cell Transplant and Cellular Therapy, Thammasat University, Pathumthani, Thailand.
9
Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA.
10
Peking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
11
IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Sapienza, University of Rome, Italy.
12
Department of Medicine and Surgery, University of Parma, Parma, Italy.
13
Instituto Clinico Humanitas, Rozzano Milano, Italy.
14
Fondazione Policlinico Universitario Gemelli IRCCS, Roma, Italy.
15
University of Perugia, Sant'Andrea Delle Fratte, Perugia, Italy.
16
Department of Hematology, Institut Paoli Calmettes, Marseille, France.
17
Department of Clinical Psychology, Paoli-Calmettes Institute, Marseille, France.
18
Institut Paoli-Calmette, Departement de psychologie clinique, Marseille, France.
19
Dept. of Hematology and Oncology, University Children's Hospital Tuebingen, Tuebingen, Germany.
20
Div of Hematology and Medical Oncology, Hospital Maisonneuve-Rosemont, Montreal, QC, Canada.
21
Hematology-Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
22
Blood and Marrow Transplant Program at Northside Hospital, Atlanta, GA, USA.
23
Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
24
Hematology Dept, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
25
Hospital Universitario Gregorio Marañón, Madrid, Spain.
26
Dmitriy Rogachev Federal Center for Pediatric Hematology, Oncology and immunology, Moscow, Russia.
27
University Hospitals Seidman Cancer Center, Cleveland, OH, USA.
28
Division of hematology/oncology, University of Virginia Health System, Charlottesville, VA, USA.
29
Maria Sklodowska-Curie Institute - Oncology Center, Gliwice Branch, Gliwice, Poland.
30
Laboratory of Hematology, University of Liège, Liège, Belgium.
31
Hematology and Bone Marrow Transplantation Unit, San Raffaele Scientific Institute, Milano, Italy.
32
Hematology department, Hospital Clínic de Barcelona, Barcelona, Spain.
33
Saint Antoine Hospital and University UPMC, Paris, France.
34
Bone Marrow Transplantation Unit , University Hospital of Patras, Patras, Greece.
35
Department of Hematology and Oncology, Klinikum Augsburg, Augsburg, Germany.
36
University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
37
Chaim Sheba Medical Center, Tel Aviv University, Tel-Hashomer, Israel.
38
Hôpital Saint-Antoine, AP-HP, Sorobonne University, and INSERM UMRs 938, Paris, France.

Abstract

Donor lymphocyte infusion has been used in the management of relapsed disease hematological malignancies after allogeneic hematopoietic cell transplantation. It can eradicate minimal residual disease or be used to rescue a hematological relapse, being able to induce durable remissions in a subset of patients. With the increased in the use of haploidentical hematopoietic cell transplantation, there is renewed interest in the use of donor lymphocytes to either treat or prevent disease relapse post-transplant. Published retrospective and small prospective studies have shown encouraging results with therapeutic donor lymphocyte infusion in different haploidentical transplantation platforms. In this consensus paper, finalized on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation, we summarized the available evidence on the use of donor lymphocyte infusion from haploidentical donor and provide recommendations on its therapeutic, pre-emptive and prophylactic use in clinical practice.

KEYWORDS:

Cell Therapy and Immunotherapy; Graft-versus-Host-Disease; Stem Cell Transplantation; donor lymphocyte infusion; haploidentical hematopoietic cell transplantation

PMID:
31537691
DOI:
10.3324/haematol.2019.219790
Free full text

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center